May 05, 2022 / 12:30PM GMT
Operator
Good morning, and welcome to the Baudax Bio first-quarter 2022 financial results conference call. (Operator Instructions) As a reminder, this conference is being recorded at the company's request.
I would now like to turn the call over to Sam Martin, Investor Relations. You may begin.
Sam Martin - Argot Partners - IR
Thank you, Kim. Good morning, and thank you for joining us on today's conference call to discuss Baudax Bio's first-quarter 2022 financial results. This is Sam Martin, and I'm joined today by Gerri Henwood, President and Chief Executive Officer of Baudax Bio. On today's call, Gerri will discuss the continued progress around the commercialization of ANJESO and will provide an overview of the financial highlights from the first quarter. We will then open the call up for questions.
Yesterday afternoon, we issued a press release detailing our financial results for the first-quarter 2022. The press release, along with the slide presentation that we will reference for today's call, is available on the Events page of the News &
Q1 2022 Baudax Bio Inc Earnings Call Transcript
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot